Pemetrexed Injection
Pemetrexed Injection is a chemotherapy medicine used to treat certain types of non-small cell lung cancer and malignant pleural mesothelioma.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 33 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Pemetrexed Injection: Patient Information Guide
A plain-language walkthrough of Pemetrexed Injection — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Pemetrexed Injection is a chemotherapy used across several cancer diagnoses. Here is the full list of supported uses:
- In combination with pembrolizumab and platinum chemotherapy, for the initial treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in patients with no EGFR or ALK genomic tumor mutations
- In combination with cisplatin, for the initial treatment of locally advanced or metastatic non-squamous NSCLC
- As a single agent for maintenance treatment of locally advanced or metastatic non-squamous NSCLC in patients whose disease has not progressed after four cycles of platinum-based first-line chemotherapy
- As a single agent for the treatment of recurrent, metastatic non-squamous NSCLC after prior chemotherapy
- In combination with cisplatin, for the initial treatment of unresectable malignant pleural mesothelioma in patients who are not candidates for curative surgery
- Not indicated for squamous cell non-small cell lung cancer
⚙️How it works▾
Pemetrexed is a folate analog metabolic inhibitor — it mimics folate (a B vitamin) to get inside cancer cells, then blocks key enzymes those cells need to build DNA and RNA. Specifically, it inhibits enzymes called thymidylate synthase, dihydrofolate reductase, and GARFT, all of which are essential for making the nucleotides (building blocks) that dividing cells require. Once inside the cell, pemetrexed is converted into longer-lasting forms that remain active and continue blocking these enzymes, helping to stop cancer cells from replicating.
💊How it's taken▾
Pemetrexed Injection is given as an intravenous (IV) infusion — into a vein — by a healthcare professional, typically over about 10 minutes on Day 1 of a 21-day cycle. The exact number of cycles depends on which condition is being treated, the treatment combination used, and how well the patient tolerates the drug.
- Before and during treatment, patients must take daily oral folic acid, receive intramuscular vitamin B12 injections every 3 cycles, and take dexamethasone (a steroid) around the time of each infusion
- Kidney function is checked before each cycle — the drug cannot be given if kidney function falls below a certain threshold
- Blood counts are monitored at the beginning and during each cycle; the next cycle may be delayed or the dose adjusted if counts are too low
Follow your oncology team's instructions exactly. Do not adjust vitamins, steroids, or timing on your own.
🤒Side effects — in detail▾
The most common side effects depend on how pemetrexed is given:
- As a single agent: fatigue, nausea, and loss of appetite
- With cisplatin: vomiting, low white blood cell counts (neutropenia), anemia, mouth and throat sores, low platelets, and constipation
- With pembrolizumab and platinum chemotherapy: fatigue or weakness, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, shortness of breath, and fever
- Lab abnormalities commonly seen include high blood sugar, elevated liver enzymes, low sodium, low phosphate, and low red/white blood cell and platelet counts
Seek immediate medical attention for signs of serious infection (fever, chills), unusual bleeding, severe shortness of breath, blistering skin, or significant changes in urination — these can signal rare but life-threatening reactions.
⚠️Warnings & precautions▾
- Bone marrow suppression (myelosuppression): Pemetrexed can severely lower blood cell counts, raising the risk of serious infection, bleeding, and anemia. Taking folic acid and vitamin B12 as directed reduces this risk significantly. Blood counts are checked before every cycle.
- Kidney failure: Pemetrexed can cause severe or even fatal kidney damage. Kidney function must be measured before each dose. The drug cannot be given if kidney function drops too low.
- Serious skin reactions: Rare but life-threatening blistering or peeling skin reactions (including Stevens-Johnson Syndrome) can occur. Treatment must be permanently stopped if these develop.
- Interstitial pneumonitis (lung inflammation): New or worsening cough, shortness of breath, or fever should be reported immediately. If confirmed, pemetrexed must be permanently discontinued.
- Radiation recall: Pemetrexed can trigger inflammation or blistering in areas of the body that received radiation — even years earlier. Report any such reactions promptly.
- Embryo-fetal toxicity: This drug can cause serious birth defects and fetal harm. Effective contraception is required during treatment and for several months after the last dose for both men and women.
🔀What it interacts with▾
Pemetrexed Injection can interact with certain drugs that affect how it is cleared from the body:
- Ibuprofen: Blocks a kidney transporter (OAT3) that helps remove pemetrexed, raising its level in the blood by about 20% — avoid for 2 days before and after each treatment, especially if kidney function is already reduced
- Other OAT3 inhibitors: Any drug that blocks the OAT3 transporter can similarly raise pemetrexed exposure and increase the risk of serious side effects — avoid when possible
- NSAIDs (non-steroidal anti-inflammatory drugs) in general: Discuss all anti-inflammatory pain relievers with your care team before using them during treatment
- Aspirin at low-to-moderate doses: Does not appear to affect pemetrexed blood levels at doses up to 325 mg every 6 hours
- Cisplatin and carboplatin: Used together with pemetrexed in several regimens — neither drug significantly changes the other's blood levels, but both require careful monitoring
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Do not use pemetrexed if you have had a severe allergic reaction to it in the past — this is a contraindication
- Tell your doctor if your kidney function is reduced — the drug cannot be used if creatinine clearance is below 45 mL/min, and closer monitoring is needed for mild to moderate impairment
- Tell your doctor about all medicines you take, especially ibuprofen and other NSAIDs
- If you are pregnant or may become pregnant, discuss the risks — this drug can cause serious birth defects
- Women of childbearing age must use effective contraception during treatment and for 6 months after the last dose
- Men with partners who could become pregnant must use effective contraception during treatment and for 3 months after the last dose
- Do not breastfeed during treatment or for 1 week after the last dose
- This drug may impair male fertility — it is not known if the effect is reversible
- Safety and effectiveness in children have not been established
- Folic acid, vitamin B12, and dexamethasone must be started before the first infusion and continued as directed — these are not optional
🚑If you take too much▾
There is no approved antidote for a pemetrexed overdose. Based on animal studies, leucovorin (a folate-related drug) may help reduce the toxic effects of too much pemetrexed, but this has not been confirmed in people. It is not known whether pemetrexed can be removed from the body by dialysis.
📡Pharmacodynamics — effects in the body▾
Pemetrexed works by disrupting the processes cancer cells use to replicate. In lab studies, it inhibited the growth of mesothelioma cancer cell lines and showed enhanced effects when combined with cisplatin. The depth of the drop in neutrophils (a type of white blood cell) during treatment is linked to how much pemetrexed is in the body, and taking folic acid and vitamin B12 helps limit how severe that drop becomes. Importantly, this effect on neutrophil counts does not worsen with repeated cycles of treatment.
🔬Pharmacokinetics — how your body processes it▾
After an IV infusion, pemetrexed distributes throughout the body and is about 81% bound to proteins in the blood. It is largely not broken down by the liver and is instead excreted mostly unchanged in the urine — 70 to 90% is recovered within the first 24 hours. The drug's half-life (the time it takes for the body to clear half of it) is about 3.5 hours in people with normal kidney function, but this increases as kidney function declines, meaning the drug stays in the body longer and reaches higher levels. Age and sex do not meaningfully affect how the body handles pemetrexed.
📦How to store it▾
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) .
📄 Written from Pemetrexed Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
Supplements & herbs that interact with Pemetrexed Injection
4 supplements and herbal products have documented interactions with Pemetrexed Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Pemetrexed Injection — the kind of thing our pharmacy team would talk through with you at the counter.
Why do I have to take vitamins and a steroid along with my chemo — are they really necessary? ▾
Can I take ibuprofen or Advil while I'm on this treatment? ▾
What side effects should I just expect, and which ones mean I need to call someone right away? ▾
Is this drug safe to use if I'm thinking about having children someday? ▾
My kidneys aren't in perfect shape. Does that affect my treatment? ▾
I had radiation treatment in the past. Is that something my oncology team should know about? ▾
Is Pemetrexed Injection available over the counter? ▾
When was Pemetrexed Injection first available? ▾
Who makes Pemetrexed Injection? ▾
💬 Answers drafted from Pemetrexed Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Pemetrexed Injection comes
Pemetrexed Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Used intravenously, in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of metastatic non-squamous non-small cell lung cancer with no EGFR or ALK tumor mutations
- Used intravenously, in combination with cisplatin, for the initial treatment of locally advanced or metastatic non-squamous non-small cell lung cancer
- Used intravenously as a single agent for maintenance treatment of locally advanced or metastatic non-squamous non-small cell lung cancer after platinum-based chemotherapy
- Used intravenously, in combination with cisplatin, for initial treatment of unresectable malignant pleural mesothelioma
- Given as an intravenous infusion over approximately 10 minutes on Day 1 of each 21-day cycle
- Folic acid must be taken by mouth once daily starting 7 days before the first infusion and continued until 21 days after the last dose
- Vitamin B12 is injected into the muscle 1 week before the first infusion and then every 3 cycles — oral B12 cannot be substituted
- Dexamethasone is taken by mouth twice daily for 3 days, beginning the day before each infusion, to reduce skin side effects
Show 7 more strengths Show fewer strengths
📊 Pemetrexed Injection across the U.S. market
How Pemetrexed Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Pemetrexed Injection is used
A general measure of how commonly Pemetrexed Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Pemetrexed Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Pemetrexed Injection prescribed? Of the 1,594 medications we measure, Pemetrexed Injection ranks #970 by Medicaid prescriptions — more than 39% of them.
Utilization by Pemetrexed Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
pemetrexed 500 MG Injection Most dispensed
Summed across the 12 of 27 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1728072
pemetrexed 100 MG Injection
Summed across the 10 of 28 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1728077
pemetrexed 25 MG/ML Injectable Solution
Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2590672
pemetrexed 1000 MG Injection
Summed across the 1 of 11 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2601728
50 ML pemetrexed 10 MG/ML Injection
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2637968
4 ML pemetrexed 25 MG/ML Injection
Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2602366
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Pemetrexed Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 26 of 77 listed Pemetrexed Injection NDCs with Medicaid activity.
🔍 Compare Pemetrexed Injection products
A representative set of FDA-listed product records for Pemetrexed Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 25 mg/mL | Intravenous | Acacia Pharma, Ltd. | NDA | View NDC → |
| 25 mg/mL | Intravenous | Accord Healthcare Inc. × 2 listings | NDA | View NDC → |
| 100 mg/4 mL | Intravenous | Accord Healthcare Inc. × 3 listings | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Accord Healthcare Inc. × 3 listings | ANDA | View NDC → |
| 1 g/40 mL | Intravenous | Accord Healthcare Inc. × 3 listings | ANDA | View NDC → |
| 100 mg/10 mL | Intravenous | Amneal Pharmaceuticals LLC × 2 listings | NDA | View NDC → |
| 100 mg/10 mL | Intravenous | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Amneal Pharmaceuticals LLC × 2 listings | ANDA | View NDC → |
| 500 mg/50 mL | Intravenous | Amneal Pharmaceuticals LLC × 2 listings | NDA | View NDC → |
| 1000 mg/100 mL | Intravenous | Amneal Pharmaceuticals LLC × 2 listings | NDA | View NDC → |
| 100 mg/4 mL | Intravenous | Apotex Corp × 2 listings | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Apotex Corp × 2 listings | ANDA | View NDC → |
| 750 mg/30 mL | Intravenous | Apotex Corp × 3 listings | ANDA | View NDC → |
| 1000 mg/40 mL | Intravenous | Apotex Corp × 2 listings | ANDA | View NDC → |
| 100 mg/4.2 mL | Intravenous | Athenex Pharmaceutical Division, LLC. × 2 listings | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Athenex Pharmaceutical Division, LLC. × 2 listings | ANDA | View NDC → |
| 100 mg/4 mL | Intravenous | Avyxa Pharma, LLC × 2 listings | NDA | View NDC → |
| 500 mg/20 mL | Intravenous | Avyxa Pharma, LLC × 2 listings | NDA | View NDC → |
| 100 mg/10 mL | Intravenous | Baxter Healthcare Corporation × 2 listings | ANDA | View NDC → |
| 500 mg/50 mL | Intraventricular | Baxter Healthcare Corporation × 2 listings | ANDA | View NDC → |
| 1000 mg/40 mL | Intravenous | Biocon Pharma Inc | ANDA | Find on DailyMed ↗ |
| 100 mg/4 mL | Intravenous | BluePoint Laboratories × 7 listings | ANDA | View NDC → |
| 100 mg/4 mL | Intravenous | BluePoint Laboratories | NDA | View NDC → |
| 500 mg/20 mL | Intravenous | BluePoint Laboratories × 7 listings | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | BluePoint Laboratories | NDA | View NDC → |
| 750 mg/30 mL | Intravenous | BluePoint Laboratories | ANDA | View NDC → |
| 850 mg/34 mL | Intravenous | BluePoint Laboratories | NDA | View NDC → |
| 1 g/40 mL | Intravenous | BluePoint Laboratories | ANDA | View NDC → |
| 1000 mg/40 mL | Intravenous | BluePoint Laboratories × 2 listings | ANDA | View NDC → |
| 1000 mg/40 mL | Intravenous | BluePoint Laboratories | NDA | View NDC → |
| 100 mg/4 mL | Intravenous | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 100 mg/4 mL | Intravenous | Dr. Reddys Laboratories Inc | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Dr. Reddys Laboratories Inc | ANDA | View NDC → |
| 1 g/40 mL | Intravenous | Dr. Reddys Laboratories Inc | ANDA | View NDC → |
| 25 mg/mL | Intravenous | Eagle Pharmaceuticals, Inc. × 3 listings | NDA | View NDC → |
| 100 mg/4 mL | Intravenous | Eli Lilly and Company × 2 listings | NDA | View NDC → |
| 100 mg/4 mL | — | Eli Lilly and Company × 2 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 500 mg/20 mL | Intravenous | Eli Lilly and Company × 2 listings | NDA | View NDC → |
| 500 mg/20 mL | — | Eli Lilly and Company × 2 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 100 mg/4 mL | Intravenous | Eugia US LLC × 2 listings | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Eugia US LLC × 2 listings | ANDA | View NDC → |
| 1000 mg/40 mL | Intravenous | Eugia US LLC × 2 listings | ANDA | View NDC → |
| 100 mg/4 mL | Intravenous | Fresenius Kabi USA, LLC × 3 listings | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Fresenius Kabi USA, LLC × 3 listings | ANDA | View NDC → |
| 750 mg/30 mL | Intravenous | Fresenius Kabi USA, LLC × 3 listings | ANDA | View NDC → |
| 1 g/40 mL | Intravenous | Fresenius Kabi USA, LLC × 3 listings | ANDA | View NDC → |
| 25 mg/mL | Intravenous | Hospira, Inc. × 2 listings | NDA | View NDC → |
| 100 mg/4 mL | Intravenous | Hospira, Inc. × 4 listings | NDA | View NDC → |
| 500 mg/20 mL | Intravenous | Hospira, Inc. × 4 listings | NDA | View NDC → |
| 1 g/40 mL | Intravenous | Hospira, Inc. × 4 listings | NDA | View NDC → |
| 100 mg/4 mL | Intravenous | Ingenus Pharmaceuticals, LLC × 2 listings | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Ingenus Pharmaceuticals, LLC × 2 listings | ANDA | View NDC → |
| 100 mg/4 mL | — | Lilly France × 2 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 500 mg/20 mL | — | Lilly France × 2 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 100 mg/4.2 mL | Intravenous | Meitheal Pharmaceuticals Inc. | ANDA | View NDC → |
| 100 mg/10 mL | Intravenous | Meitheal Pharmaceuticals Inc. × 8 listings | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Meitheal Pharmaceuticals Inc. | ANDA | View NDC → |
| 500 mg/50 mL | Intravenous | Meitheal Pharmaceuticals Inc. × 8 listings | ANDA | View NDC → |
| 750 mg/30 mL | Intravenous | Meitheal Pharmaceuticals Inc. | ANDA | View NDC → |
| 1 g/40 mL | Intravenous | Meitheal Pharmaceuticals Inc. | ANDA | View NDC → |
| 100 mg/10 mL | Intravenous | NorthStar RxLLC | ANDA | View NDC → |
| 500 mg/50 mL | Intravenous | NorthStar RxLLC | ANDA | View NDC → |
| 100 mg/4 mL | Intravenous | Qilu Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Qilu Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 100 mg/4.2 mL | Intravenous | Sagent Pharmaceuticals | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Sagent Pharmaceuticals | ANDA | View NDC → |
| 100 mg/4 mL | Intravenous | Sandoz Inc. × 3 listings | NDA | View NDC → |
| 500 mg/20 mL | Intravenous | Sandoz Inc. × 3 listings | NDA | View NDC → |
| 1000 mg/40 mL | Intravenous | Sandoz Inc. × 3 listings | NDA | View label ↗ |
| 100 mg/10 mL | Intravenous | Shilpa Medicare Limited × 2 listings | NDA | View NDC → |
| 500 mg/50 mL | Intravenous | Shilpa Medicare Limited × 2 listings | NDA | View NDC → |
| 1000 mg/100 mL | Intravenous | Shilpa Medicare Limited × 2 listings | NDA | View NDC → |
| 100 mg | Intravenous | Solco Healthcare US, LLC | ANDA | View NDC → |
| 100 mg/4 mL | Intravenous | Somerset Therapeutics LLC | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Somerset Therapeutics LLC | ANDA | View NDC → |
| 25 mg/mL | Intravenous | Teva Pharmaceuticals, Inc. × 9 listings | NDA | View NDC → |
| 100 mg/4 mL | Intravenous | Waverley Pharma Inc × 2 listings | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Waverley Pharma Inc × 2 listings | ANDA | View NDC → |
| 100 mg/100 mg | — | Wuhan Calmland Pharmaceuticals Co., Ltd. × 2 listings | BULK INGREDIENT | View NDC → |
| 100 mg/4 mL | Intravenous | Zydus Lifesciences Limited | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Zydus Lifesciences Limited | ANDA | View NDC → |
| 1000 mg/40 mL | Intravenous | Zydus Lifesciences Limited | ANDA | View NDC → |
| 100 mg/4 mL | Intravenous | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 1000 mg/40 mL | Intravenous | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
Showing 186 of 186 products — FDA National Drug Code Directory. See every product, package size and price: browse all 186 Pemetrexed Injection NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Pemetrexed Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Pemetrexed Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Pemetrexed Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 68446 2 dose forms · 12 strengths
-
Dose form (SCDF) Injectable Solution RxCUI 2590671In current FDA listingsClinical drug / strength (SCD) 25 MG/MLRxCUI 2590672 -
Dose form (SCDF) Injection RxCUI 1728071In current FDA listingsClinical drug / strength (SCD) 4 ML pemetrexed 25 MG/MLRxCUI 260236610 ML pemetrexed 10 MG/MLRxCUI 263795820 ML pemetrexed 25 MG/MLRxCUI 260236334 ML pemetrexed 25 MG/MLRxCUI 260534140 ML pemetrexed 25 MG/MLRxCUI 260236550 ML pemetrexed 10 MG/MLRxCUI 2637968100 MGRxCUI 1728077100 ML pemetrexed 10 MG/MLRxCUI 2637966500 MGRxCUI 1728072750 MGRxCUI 26021361000 MGRxCUI 2601728
Look up RxCUI 68446 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Pemetrexed Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
…and 7 more on the FDA NDC directory.
RxNorm drug class
Pemetrexed Injection belongs to the Folate Analog Metabolic Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 33 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Teva Pharmaceuticals, Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.